Alle Storys
Folgen
Keine Story von EvaluatePharma Ltd mehr verpassen.

EvaluatePharma Ltd

EvaluatePharma Appoints Alexander Karle as COO

Boston (ots/PRNewswire)

EvaluatePharma [http://www.evaluategroup.com](R), the premier source for life science sector analysis and consensus forecasts, has appointed Alexander Karle as Chief Operating Officer. Karle's experience in formulating customer-centric growth strategies and leading them to successful implementation will be instrumental in driving EvaluatePharma's continued expansion within key industry sectors and geographic markets.

Prior to joining EvaluatePharma, Karle served as Vice President of Strategy and Development for global intelligence firm Thomson Reuters. There, he served on the executive leadership team and was responsible for defining and leading the corporate growth strategy for Thomson Reuters' intellectual property and science division, an $800M+ information and services business. Karle also led the restructuring of Thomson Reuters' pharmaceutical benchmarking business, CMR International, where he set strategy and defined new services to integrate with Thomson Reuters' life sciences business. Karle began his professional career as a Senior Associate at Booz Allen & Hamilton. Karle holds a Bachelor of Arts in business, economics and law from the European Business Programme in Mu?nster, Germany and Hull, United Kingdom as well as a Master of Business Administration from Yale University's School of Management.

"Alexander brings a breadth of experience in driving corporate development for global intelligence firms within the life sciences. His expertise in driving successful operational growth for Thomson Reuters' science and healthcare businesses will be incredibly relevant," said Dr. Jonathan de Pass, EvaluatePharma CEO. "We are thrilled to welcome someone of his caliber to our executive leadership team."

About EvaluatePharma

Since 1996, EvaluatePharma has been the premier source for life science sector analysis, delivering exclusive, trusted commercial insight into industry performance through its proprietary platform. EvaluatePharma is staffed by a team of over 85 dedicated healthcare analysts employing rigorous methodologies to deliver the most-up-to-date commercial performance data available. An award winning editorial team of journalists writing under the EP Vantage [http://www.epvantage.com] name support EvaluatePharma's analysis. The EvaluatePharma services enable the life science community to make sound business decisions about value and opportunity. For more information please visit http://www.EvaluatePharma.com.

Media Contacts: EvaluatePharma Christine Lindgren +1-617-866-3906 christinel@EvaluatePharma.com Chempetitive Group Erik Clausen +1-858-457-2436 rlear@chempetitive.com

Weitere Storys: EvaluatePharma Ltd
Weitere Storys: EvaluatePharma Ltd
  • 26.04.2012 – 13:02

    EvaluatePharma 2018 Outlook: Novartis #1 and Pfizer Sole USA Co in Top 5

    London (ots/PRNewswire) - EvaluatePharma Ltd, a leading source for life science sector analysis and the first to supply reliable consensus forecasts of global drug sales, revealed today that Novartis is expected to take the top spot amongst the world's pharmaceuticals manufacturers, in terms of prescription (Rx) drug sales, starting in 2014 and remains at the top ...

  • 15.11.2011 – 21:43

    Linking EudraCT and ClinicalTrials.gov Records Provides Huge Benefit

    London, November 15 (ots/PRNewswire) - EvaluatePharma Ltd, a leading source for life science sector analysis and the first to supply consensus forecasts of global drug sales, announced today the launch of its new clinical trial intelligence service, EP Clinical Trials [http://www.evaluatepharma.com/clinical ][SM]. By linking EudraCT [https://eudract.ema.europa.eu ] and ...

  • 01.11.2011 – 10:09

    Sanofi Tops Pfizer as Number One for Global Pharma Sales

    London, November 1 (ots/PRNewswire) - EvaluatePharma Ltd, a leading source for life science sector analysis and the first to supply reliable consensus forecasts of global drug sales, revealed today that Sanofi is expected to take the top spot amongst the world's pharmaceuticals manufacturers in 2012 and hold it through 2016. The French drug maker has raced up the rankings over the last decade largely through M&A activity, ...